Cellectis (CLLS) Free Cash Flow (QoQ) (2015 - 2026)
Cellectis (CLLS) Free Cash Flow (QoQ) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,184.45 Bn | 68,184.17 Bn | - |
| 2 | Nanobiotix | 1,953.19 Bn | 1,953.13 Bn | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - |
| 4 | BeOne Medicines | 474.39 Bn | 469.59 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.21 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.92 Bn | 61.16 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.43 Bn | 63.43 Bn | - |
| 8 | Argenx Se | 56.67 Bn | 51.49 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 38.08 Bn | 38.08 Bn | - |
| 10 | Cellectis | 288.51 Mn | 102.85 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.73% |
| Dec 31, 2025 | -3,643.85% |
| Sep 30, 2025 | 96.10% |
| Jun 30, 2025 | 40.32% |
| Mar 31, 2025 | -259.53% |
| Dec 31, 2024 | 7.70% |
| Sep 30, 2024 | -109.49% |
| Jun 30, 2024 | 330.41% |
| Mar 31, 2024 | -167.53% |
| Dec 31, 2023 | 303.83% |
| Sep 30, 2023 | 1.89% |
| Jun 30, 2023 | 34.57% |
| Mar 31, 2023 | -1,105.67% |
| Dec 31, 2022 | 90.34% |
| Sep 30, 2022 | -27.94% |
| Jun 30, 2022 | 39.81% |
| Mar 31, 2022 | 49.66% |
| Dec 31, 2021 | -124.22% |
| Sep 30, 2021 | -286.71% |
| Jun 30, 2021 | 79.61% |